Corporate | 29 April 2013 07:28
Evotec AG / Key word(s): Miscellaneous
29.04.2013 / 07:28
---------------------------------------------------------------------
Hamburg, Germany - 29 April 2013: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced that Evotec (US) Inc. has
executed a multi-year lease on a facility specifically designed to expand
the offering of its Compound Management Services on the East Coast of the
United States.
The facility, located in Branford Connecticut, is strategically positioned
to support the strong presence of Evotec's drug discovery collaborators
along the East Coast of the United States. The new facility will be modern,
cost effective and scalable for continued growth. The investment into
industry leading technologies, specifically aimed at library management,
and the access to incremental space will enable Evotec to better support
the East Coast pharmaceutical and biopharmaceutical industry for the coming
years. The facility will be fully operational early Q3 2013 and will
complement the existing facility in South San Francisco which will continue
to be fully operational and serve existing clients.
Scott Snyder, Executive Vice President Compound Management of Evotec,
commented: 'This is an important strategic expansion of our EVT Execute
compound management offering which Evotec first acquired in South San
Francisco in 2011. The significant investment will enable Evotec to better
compete for East Coast compound management opportunities and continue to
provide the very best services and solutions to our partners.'
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
End of Corporate News
---------------------------------------------------------------------
29.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
208831 29.04.2013